Upregulation of mir-221 and mir-222 in atypical teratoid/rhabdoid tumors: Potential therapeutic targets

Simone Treiger Sredni, Maria De Fátima Bonaldo, Fabrício Falconi Costa, Chiang Ching Huang, Christopher Allan Hamm, Veena Rajaram, Tadanori Tomita, Stewart Goldman, Jared Marshall Bischof, Marcelo Bento Soares

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


Purpose: The aim of this study is to search for new therapeutic targets for atypical teratoid-rhabdoid tumors (ATRT). Methods: To achieve this, we compared the expression of 365 microRNAs among ATRT, medulloblastomas, and normal brain. Results: MiR-221 and miR-222 were within the top differentially expressed microRNAs. The deregulated expression of miR221/222 was demonstrated to inhibit the expression of the tumor suppressor and inhibitor of cell cycle p27 Kip1. Here, we demonstrated the negative regulation of p27 Kip1 by miR-221/222 in ATRT using microarray, real-time reverse transcriptase polymerase chain reaction, and immunohistochemistry. Conclusion: As anti-miR therapy was recently proposed as an alternative treatment for cancer, these findings suggest that anti-miR-221/222 therapy might have therapeutic potential in ATRT.

Original languageEnglish (US)
Pages (from-to)279-283
Number of pages5
JournalChild's Nervous System
Issue number3
StatePublished - 2010


  • Atypical teratoid/rhabdoid tumors
  • MiR221
  • MiR222
  • P27

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology


Dive into the research topics of 'Upregulation of mir-221 and mir-222 in atypical teratoid/rhabdoid tumors: Potential therapeutic targets'. Together they form a unique fingerprint.

Cite this